The in vitro antimicrobial activity of ciprofloxacin (Bay o 9867) was compared with those of the other new fluorated piperazinyl-substituted quinoline derivatives: norfloxacin, ofloxacin, and pefloxacin, as well as with those of the earlier analogs, nalidixic acid and oxolinic acid. Virtually no resistance against the new fluorated piperazinyl-substituted quinoline derivatives was observed. As a rule, ciprofloxacin was about four times more active in vitro than the other new fluorated piperazinyl-substituted quinoline derivatives. [4] ). These products are structurally related to the other naphthyridine and quinoline derivatives, such as nalidixic acid and oxolinic acid ( Fig. 1 ), but show an expanded antibacterial spectrum. Furthermore, no cross resistance has been described between the earlier analogs and the fluorated piperazinyl-substituted quinoline derivatives.
Since 1980, a number of fluorated piperazinyl-substituted quinoline derivatives have been synthesized by Japanese research laboratories alone (norfloxacin by Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan [2] ; ofloxacin by Daiichi Seiyaku Co., Ltd., Tokyo, Japan [3] ) or in cooperation with European research laboratories (pefloxacin by Laboratoires Roger Bellon, Paris, France [1] ) or by European research laboratories alone (ciprofloxacin by Bayer AG, Wuppertal, West Germany [4] ). These products are structurally related to the other naphthyridine and quinoline derivatives, such as nalidixic acid and oxolinic acid ( Fig. 1 ), but show an expanded antibacterial spectrum. Furthermore, no cross resistance has been described between the earlier analogs and the fluorated piperazinyl-substituted quinoline derivatives.
The purpose of this study was to compare all the fluorated piperazinyl-substituted quinoline derivatives.
The antibiotics were provided by their respective manufacturers. A total of 343 bacterial isolates included specimens recently isolated from patients hospitalized at the Akademisch Ziekenhuis Antwerpen, Antwerp, Belgium, as well as isolates which had been stored frozen because of some unique feature, such as pattern of resistance, pathogenicity, and rarity of occurrence.
Antibiotic solutions were prepared in appropriate buffer solutions or distilled water or both.
Antibacterial activity was determined by the agar dilution technique with Mueller-Hinton medium (Difco Laboratories; GIBCO Diagnostics) supplemented with 10% whole human blood to support the growth of streptococci and with 5% lysed human blood and vitamin K for anaerobic bacteria.
The inoculum was a 1-,ul Virtually no resistance against ciprofloxacin was noted among the 343 strains tested, with MICs required to inhibit the majority of isolates ranging between 0.008 ,ug/ml or less and 0.5 ,ug/ml. The few exceptions, requiring for inhibition MICs above 0.5 ,ug/ml, were Providencia sp.
(1 strain of 6 tested), Flavobacterium sp. (3 strains of 3 tested), Achromobacter sp. (2 strains of 2 tested), Acinetobacter sp.
(1 strain of 8 tested), Pseudomonas maltophilia (3 strains of 4 tested), Streptococcus group D (9 strains of 21 tested), and Bacteroides fragilis (13 strains of 13 tested).
The activities of ciprofloxacin and the other fluorated piperazinyl-substituted quinoline derivatives, norfloxacin, ofloxacin and pefloxacin, as well as the earlier analogs, nalidixic acid and oxolinic acid, are shown in Table 1 .
Against members of the family Enterobacteriaceae, ciprofloxacin was the most active new compound, being four-to eightfold more active than norfloxacin, ofloxacin, and pefloxacin. Against staphylococci, ciprofloxacin, ofloxacin, and pefloxacin were equally active. Against Pseudomonas aeruginosa, ciprofloxacin and norfloxacin were the most active compounds (ciprofloxacin still being two times more active than norfloxacin). The MIC of ciprofloxacin for inhibition of P. aeruginosa ranged from 0.063 to 0.5 ,ug/ml. Interestingly, the earlier quinoline derivative, oxolinic acid, displayed appreciable antipseudomonal activity in vitro, with an MIC required to inhibit 75% of organisms of 8 ,ug/ml (urinary breakpoints for this chemotherapeutic being 4 and 16 ig/ml).
Against streptococci, ciprofloxacin and ofloxacin were the most active compounds. Against Bacteroidesfragilis, ofloxacin was more active than ciprofloxacin and pefloxacin (factor 2), whereas norfloxacin is inactive in this study.
The susceptibility of nalidixic acid-or oxolinic acidresistant, gram-negative bacterial strains for the fluorated piperazinyl-substituted quinoline derivatives was found to be slightly diminished. MICs were, however, still extremely low ( Fig. 2 and 3) . No cross-resistance with the earlier analogs was observed.
Another striking feature of the quinoline and naphthyridine derivatives was the almost fixed relationship between their activities, as demonstrated by regression analysis of MIC pairs for individual Klebsiella strains (n = 24) ( Table 2 ). This common pattern suggests that resistance to one of the new fluorated piperazinyl-substituted quinoline derivatives will probably mean resistance to the rest of the group also. The fluorated piperazinyl-substituted quinoline derivatives constitute a new class of chemotherapeutic agents with a distinct, unusually wide spectrum which includes aerobic and facultatively anaerobic gram-positive and gram-negative bacteria and, in the case of ofloxacin, ciprofloxacin, and pefloxacin, even anaerobic bacteria. There was no cross resistance with the earlier analogs, e.g., oxolinic acid and nalidixic acid, and the intrinsic activity of the new compounds was considerably higher than those of the latter.
